Welcome to our dedicated page for Carisma Therapeutics news (Ticker: CARM), a resource for investors and traders seeking the latest updates and insights on Carisma Therapeutics stock.
Carisma Therapeutics Inc. (CARM) generates news primarily as a clinical-stage biopharmaceutical company that has focused on engineered macrophage and monocyte immunotherapies and, more recently, on corporate restructuring and wind down activities. News coverage of CARM reflects both its scientific developments and its significant corporate and listing transitions.
On the scientific side, Carisma has issued press releases on preclinical and clinical milestones across oncology and fibrosis. These include data on CT-0525, an ex vivo CAR-monocyte therapy for HER2-overexpressing solid tumors, CT-1119 for mesothelin-positive tumors, and engineered macrophage programs for liver fibrosis. The company has also reported preclinical results from its anti-GPC3 in vivo CAR-M program for hepatocellular carcinoma, developed in collaboration with Moderna, highlighting tumor-targeting activity and off-the-shelf potential.
Carisma news has also covered conference participation, with company representatives presenting at events such as the Society for Immunotherapy of Cancer (SITC), the American Association for the Study of Liver Diseases (AASLD) Liver Meeting, and healthcare investor conferences hosted by firms like Oppenheimer, Evercore ISI, and H.C. Wainwright. These announcements often summarize new data, poster presentations, and updates on the company’s pipeline strategy.
More recent news has focused on strategic alternatives, restructuring, and listing status. Carisma has announced workforce reductions, the pausing or discontinuation of certain programs, and a revised operating plan centered on evaluating strategic options and preserving capital. Additional releases have detailed the company’s noncompliance with Nasdaq listing requirements, the suspension of trading on Nasdaq, the commencement of trading on the OTCID market tier, and the Board’s decision to voluntarily delist and deregister its common stock as part of an orderly wind down of operations.
Investors and observers following the CARM news feed can review this sequence of scientific, strategic, and regulatory announcements to understand how Carisma’s macrophage engineering platform evolved, how its collaboration with Moderna changed over time, and how the company moved from active development to asset monetization and wind down planning.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 14, 2023, Carisma Therapeutics (Nasdaq: CARM) announced that three abstracts were accepted for presentation at the AACR Annual Meeting from April 14-19 in Orlando, FL. The presentations highlight Carisma's innovative cell therapy platform focused on engineered macrophages for treating difficult cancers. Key studies include a Phase 1 trial of autologous anti-HER2 CAR-M in HER2-positive solid tumors and advancements in a mesothelin-targeting CAR-M program. These findings demonstrate the potential of macrophage-based therapies to improve outcomes for patients with advanced solid tumors. Carisma aims to address immunosuppression and inflammation in cancer treatment through its unique platforms.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has appointed Mark R. Sullivan as Chief Legal Officer and Corporate Secretary, effective immediately. Sullivan brings extensive legal expertise in the life sciences sector, having previously served as General Counsel for Sesen Bio and MModal Inc. CEO Robert Barrow expressed optimism about Sullivan's contributions during a transformative phase for MindMed, which is advancing its clinical programs targeting brain health disorders. The company is focused on developing innovative treatments and improving patient outcomes. MindMed trades under the symbol MNMD on NASDAQ and MMED on the NEO Exchange.
Carisma Therapeutics Inc. (Nasdaq: CARM) announced its participation in several key healthcare and investor conferences throughout April 2023. Highlights include:
- 2023 Cell & Gene Meeting on the Med: Tom Wilton, Chief Business Officer, will present on April 13 in Barcelona, Spain.
- AACR Annual Meeting 2023: Carisma will present three data abstracts related to engineered macrophages from April 14-19 in Orlando, Florida.
- Needham 22nd Annual Virtual Healthcare Conference: Steven Kelly, CEO, will engage in a fireside chat on April 20.
- Chardan's 7th Annual Genetic Medicines & Cell Therapy Summit: On April 24, Steven Kelly and Michael Klichinsky will participate in a fireside chat.
Webcasts of these events will be available post-presentation.
Carisma Therapeutics Inc. (Nasdaq: CARM) successfully completed its merger with Sesen Bio, commencing trading under the ticker symbol 'CARM'. The merger provided a cash position of $105.3 million, anticipated to fund operations through 2024. In 2022, the company recorded collaboration revenues of $9.8 million with Moderna and reported a net loss of $61.2 million, driven by increased research and development expenses. Key milestones include additional data from its Phase 1 CT-0508 study and submission of an IND application for CT-0525, expected in the latter half of 2023. The company aims for significant advancements in solid tumor immunotherapy.